Medicare’s Part D program has a number that almost nobody pays and everybody’s premium is built from. For 2027 it is $41.33, and the way CMS arrived at it says more about the state of drug coverage than the figure itself does. The agency did not choose that number. It is the highest number the law permitted.
The cap did the work
Under the Inflation Reduction Act, the Part D base beneficiary premium cannot rise more than 6% in a year through 2029. CMS’s July 28 announcement puts the 2027 figure at $41.33 and the national average monthly bid amount — the average of what Part D plans told Medicare it will cost to cover a standard beneficiary — at $296.05.
The actuarial memo behind the fact sheet shows the arithmetic, and it is worth seeing. The statute requires taking the lesser of two calculations. The first is simply last year’s base premium raised by 6%: $38.99 × 1.06 = $41.33. The second, the formula that would apply without the cap, produced $94.06. CMS took the lesser, so the base premium landed at $41.33 — meaning the uncapped calculation was more than twice what beneficiaries will see. The cap is not trimming an edge off this number. It is holding back most of it.
Free retirement updates: Social Security and Medicare change every year, and nobody sends you a memo. Our free Retirement Shield newsletter breaks down what changed and what to do. Get it free in your inbox.
Why $41.33 is not what you will pay
CMS is unusually direct about this, and the caution belongs near the top of any household’s reading of the number. The agency notes that actual Part D premiums paid by individual beneficiaries equal the base premium adjusted by several factors, that premiums vary significantly from one plan to another, and that in practice they “seldom equal the base beneficiary premium.”
The base premium is a benchmark. Each plan’s own premium is computed by comparing that plan’s bid to the national average bid and adjusting from there, which is why two drug plans sold in the same county can carry premiums that differ by a factor of five. A household reading “$41.33” as a forecast of next year’s bill is reading it wrong in both directions — plenty of plans will come in under it, and plenty will come in well over.
The subsidy that is ending underneath this
There is a second change in the same announcement that will matter more to standalone drug-plan customers than the capped base premium does. For the past several years CMS has run a Part D Premium Stabilization Demonstration, which paid participating standalone prescription drug plans to hold premiums down — reducing them by a set amount and capping how much any single plan’s premium could rise year over year. That demonstration ends with the 2026 plan year.
The consequence is arithmetic. A capped 6% increase in the base premium does not cap what an individual standalone plan charges, and plans that have been leaning on the demonstration to hold their premiums flat lose that support for 2027. It is entirely possible for the base premium to rise 6% while a specific drug plan’s premium rises considerably more. Anyone whose current plan has held its premium suspiciously steady for two or three years has a particular reason to check.
The September date to put on the calendar
None of the 2027 figures a household actually shops on exist yet. CMS says the Medicare Advantage and Part D landscape files — the plan-by-plan listings of premiums, deductibles and formularies for each county — along with final average premium figures, arrive in mid-to-late September. That is roughly a month before the annual enrollment period opens on October 15 and runs through December 7.
The useful sequence is to treat September as the research window and October as the decision window. When the landscape files publish and the plan year loads into Medicare’s plan comparison tool, the questions worth answering are narrow: what the plan’s 2027 premium is compared with what it charges now, whether the drugs a household actually takes are still on its formulary and at what tier, and whether the pharmacy the household uses is still preferred under that plan. Formulary changes tend to cost more than premium changes and get less attention, because a drug moving up a tier or off the list entirely does not announce itself the way a premium increase does.
It is also the moment when the marketing arrives. Enrollment season brings a heavy volume of calls, mailers and television advertising aimed at people on Medicare, and this year several federal rules that slowed those sales conversations down have been removed. A base premium set at the legal maximum is a reasonable prompt to go looking at plans; it is not a reason to make that decision on the phone with whoever calls first.
This article was produced with AI assistance and reviewed by a human editor. Figures are linked to their primary sources; where a claim could not be verified from the public record, we say so.
More Financial Reading
